Related Experiment Videos
Radioiodine therapy of euthyroid multinodular goitres
Jeroen M B Manders1, Frans H M Corstens
1University Medical Center Nijmegen, 565 Department of Nuclear Medicine, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands. j.manders@nucmed.umcn.nl
European Journal of Nuclear Medicine and Molecular Imaging
|August 23, 2002
Summary
Euthyroid multinodular goiter, characterized by thyroid enlargement, requires treatment only when causing obstructive symptoms. Radioiodine therapy is recommended for elderly patients or those with contraindications to surgery.
Area of Science:
- Endocrinology
- Nuclear Medicine
Background:
- Euthyroid multinodular goiter results from thyroid epithelial cell overgrowth, leading to progressive enlargement and nodularity.
- Clinical symptoms, such as dysphagia and dyspnea, stem directly from the enlarged thyroid gland.
Purpose of the Study:
- To compare treatment modalities for euthyroid multinodular goiter.
- To identify the optimal treatment strategy based on patient characteristics and risks.
Main Methods:
- Review of existing literature on treatments for euthyroid multinodular goiter.
- Comparative analysis of radioiodine (iodine-131), surgery, and TSH suppression therapy.
Main Results:
- Radioiodine therapy is presented as a preferred option for specific patient groups.
- The lifetime cancer risk from radioiodine is considered negligible in individuals over 65 compared to the general population.
Conclusions:
- Radioiodine is the treatment of choice for elderly patients, those with surgical contraindications, or those unwilling to undergo surgery.
- The safety profile of radioiodine in older adults supports its use in this demographic.